Evidence map›Paper›PMID 35704751›Full record

ArticleChemMedChem2022

Simple Dipyrrin Analogues of Prodigiosin for Use as Colistin Adjuvants.

Kittipan Siwawannapong, Ansley M Nemeth, Roberta J Melander, Jie Rong, Jonathan R Davis, Masahiko Taniguchi, Morgan E Carpenter, Jonathan S Lindsey, Christian Melander

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. β-Lactams from the Ocean.Marine drugs · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kittipan SiwawannapongDepartment of Chemistry, North Carolina State University, Raleigh, NC 27695, USA.
Ansley M NemethDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.
Roberta J MelanderDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.ORCID 0000-0001-8271-4696
Jie RongDepartment of Chemistry, North Carolina State University, Raleigh, NC 27695, USA.
Jonathan R DavisDepartment of Chemistry, North Carolina State University, Raleigh, NC 27695, USA.
Masahiko TaniguchiDepartment of Chemistry, North Carolina State University, Raleigh, NC 27695, USA.
Morgan E CarpenterDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.
Jonathan S LindseyDepartment of Chemistry, North Carolina State University, Raleigh, NC 27695, USA.
Christian MelanderDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.
North Carolina State University · USUniversity of Notre Dame · US

Funding

Development of Antibiotic Adjuvants for Gram-Negative BacteriaR01AI136904 · NIAID · UNIVERSITY OF NOTRE DAME · PI MELANDER, CHRISTIAN COREY · 2018 to 2022
$3.7M
NIAID NIH HHS R01 AI136904
6 · The paper itself

Abstract

Multidrug resistant (MDR) bacteria are an increasing public health problem. One promising alternative to the development of new antibiotics is the use of antibiotic adjuvants, which would allow the continued use of FDA-approved antibiotics that have been rendered ineffective due to resistance. Herein, we report a series of dipyrrins and pyrrole derivatives designed as analogues of prodigiosin and obatoclax, several of which potentiate the activity of colistin against Klebsiella pneumoniae, with lead compounds also potentiating colistin against Acinetobacter baumannii and Pseudomonas aeruginosa.

Indexed as

Acinetobacter baumanniiColistinAdjuvants, PharmaceuticAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialMicrobial Sensitivity TestsProdigiosinPseudomonas aeruginosaAdjuvants, PharmaceuticAnti-Bacterial AgentsColistinProdigiosinadjuvantantibiotic resistancecolistindipyrringram negative

Identifiers

PMID35704751
PMCPMC9391303
OpenAlexW4282938219

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.